May 15, 2025 – Amneal Pharmaceuticals Inc. has received approval for Brekiya® (dihydroergotamine mesylate) injection from the U.S. FDA for acute migraine treatment. Brekiya becomes the first and only dihydroergotamine (DHE) autoinjector that allows patients to self-administer the same medication used in hospital settings in a ready-to-use form.
The autoinjector is designed for subcutaneous administration into the thigh. It requires no refrigeration, assembly, or priming, making it more convenient for patients. This innovation provides a significant advancement in migraine and cluster headache treatment.
Brekiya injection offers a portable and user-friendly option for patients to manage acute episodes effectively. This migraine therapeutic injection has the potential to provide sustained pain relief in a convenient, easy-to-use, self-administered format.
Brekiya injection can be beneficial for patients who do not respond well to oral therapies due to inefficient efficacy, have gastroparesis, and experience vomiting or nausea during attacks. Development and approvals of such novel, effective, and easy-to-use medications will play a key role in addressing the global migraine burden.
According to Coherent Market Insights (CMI), the global migraine therapeutic market size is projected to reach USD 6,850.9 Mn in 2025 and USD 12,931.4 Mn by 2032. Global demand for migraine therapeutics will likely rise at a CAGR of 9.5% during the forecast period.
Views and Statements
Speaking on the occasion, Joe Renda, Senior VP, Chief Commercial Officer-Specialty, said, “We are excited to offer the first and only ready-to-use autoinjector for patients with cluster headaches and acute migraine.”
DHE is mostly administered in emergency rooms, headache clinics, and urgent care facilities intravenously. It can be used at any stage of a migraine attack and has the tendency to protect patients from headache recurrence.
Around 39 million Americans live with migraines, while up to one million experience cluster headaches. However, treatment options for cluster headaches are limited, making the Brekiya autoinjector a valuable new option for this underserved patient population.
“Our single-dose autoinjector offers an innovative treatment option, enabling patients to quickly self-administer medication during painful attacks without visiting the emergency room,” stated Joe Renda. Brekiya will be available in the United States by the second half of 2025.
Impact and Future Outlook
FDA’s approval of Amneal’s Brekiya marks a pivotal advancement in the treatment landscape for migraine therapeutics. It will offer a new ray of hope, particularly for patients with acute headache and cluster headache.
Patients suffering from acute migraine and cluster headaches are constantly seeking novel treatments with high efficacy and user-friendly features. Brekiya’s approval will offer a new therapeutic option that potentially improves outcomes while providing ultimate convenience.
The approval of Brekiya could encourage other pharmaceutical companies to increase their spending on research and development for developing self-administered injections for migraine relief. They will also focus on expediting the approval process to bring these therapies to market more quickly and gain a competitive edge.
Sources:
News Outlet: Reuters
Company: Amneal Pharmaceuticals Inc.
